The Indian pharmaceutical sector stands at a pivotal juncture in 2025. With regulatory changes like the Revised Schedule M and increased scrutiny from the Central Drugs Standard Control Organization (CDSCO), the focus is no longer solely on technological upgrades and infrastructure modernization. The spotlight has now shifted to the most vital asse